Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

ANTICHOLINESTERASE ACTIVITY OF 3-FORMYLCHROMONE DERIVATIVES

DOI: https://doi.org/10.29296/25877313-2021-10-04
Download full text PDF
Issue: 
10
Year: 
2021

D.I. Pozdnyakov Ph.D. (Pharm.), Associate Professor of Department of Pharmacology with Clinical Pharmacology Course, Head of Living System Laboratory, Pyatigorsk medical and pharmaceutical institute (Pyatigorsk, Russia) E-mail: pozdniackow.dmitry@yandex.ru

The aim of the study. To evaluate the anticholinesterase activity of 3-formylchromine derivatives in experimental Alzheimer's disease in rats. Material and methods. The work was performed on male Wistar rats that were modeled for Alzheimer's disease by injecting the fragment Aß1-42 into the CA1 part of the hippocampus. The test-compounds and the reference drug (ipidacrine, 1 mg / kg, per os) were administered for 60 days. Further, the preservation of the memorable trace in the Morris water maze test and the acetylcholinesterase activity by photometric method in the hippocampus were evaluated. Results. In the course of the work, it was found that among the eighteen studied substances the most pronounced anticholinesterase effect provided by 3-[(E)-3-(3,5-ditret-butyl-4-hydroxy-phenyl)-3-oxo-prop-1-enyl]-6-methoxy-chromene-4-one, the use of which at a dose of 40 mg/kg (oral), reduced the activity of hippocampus acetylcholinesterase by 50.5% (p
Keywords: 
Alzheimer's disease
anticholinesterase activity
chromone derivatives

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Wilson R.S., Segawa E., Boyle P.A., Anagnos S.E., Hizel L.P., Ben-nett D.A. The natural history of cognitive decline in Alzheimer’s disease. Psychol. Aging. 2012; 27: 1008–1017.
  2. Alzheimer's Association. 2016 Alzheimer's disease facts and fig-ures. Alzheimers Dement. 2016; 12(4): 459-509. DOI: 10.1016/j.jalz.2016.03.001. PMID: 27570871.
  3. Catanesi M. Neuroprotective potential of choline alfoscerate against β‐amyloid injury: Involvement of neurotrophic signals. Cell biology international 44.8. 2020: 1734-1744.
  4. Briggs R., Kennelly S.P., O'Neill D. Drug treatments in Alzheimer's disease. Clin Med (Lond). 2016; 16(3): 247-253. DOI:10.7861/clinmedicine.16-3-247.
  5. Pozdnjakov D.I., Rukovitsina V.M., Larskij M.V. Vlijanie pro-izvodnyh 3-formilhromona in vitro na agregatsiju chastits r-amiloida i aktivnost' tirozinazy. Voprosy biologicheskoj, meditsinskoj i farmatsevticheskoj himii. 2021; 24(1): 11-15. DOI: 10.29296/25877313-2021-01-02 [Pozdnjakov D.I., Ruko-vicina V.M., Larskij M.V. Vlijanie proizvodnyh 3-formilhromona in vitro na agregaciju chas-tic r-amiloida i aktivnost' tirozinazy. Vo-prosy bio-logicheskoj, medicinskoj i farmacevticheskoj himii. 2021; 24(1): 11-15. DOI: 10.29296/25877313-2021-01-02 (in Russ.)]
  6. Onodera K., Kojima J., Wachi M. Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998; 18(2): 33-37.
  7. Dingová D., Hrabovská A. Metódy stanovenia aktivity cholínesteráz [Methods for determination of cholinesterase activity]. Cesk Fysiol. 2015; 64(2): 79-83. Slovak.
  8. Zhang Y.Y., Yang L.Q., Guo L.M. Effect of phosphatidylserine on memory in patients and rats with Alzheimer's disease. Genet. Mol. Res. 2015; 14(3): 9325-9333. DOI: 10.4238/2015.
  9. Hampel H., Mesulam M.M., Cuello A.C. et al. The cholinergic sys-tem in the pathophysiology and treatment of Alzheimer's dis-ease. Brain. 2018;141(7):1917-1933. doi:10.1093/-brain/awy132.
  10. Mishra Pju, Kumar Aju, Panda G. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018). Bioorg. Med. Chem. 2019; 27(6): 895-930. DOI: 10.1016/j.bmc.2019.01.025.
  11. Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Mol. Med. Rep. 2019; 20(2): 1479-1487. DOI:10.3892/mmr.2019.10374
  12. Mughal E.U., Javid A., Sadiq A., Murtaza S., Zafar M.N., Khan B.A., Sumrra S.H., Tahir M.N., Kanwal, Khan K.M. Synthesis, structure-activity relationship and molecular docking studies of 3-O-flavonol glycosides as cholinesterase inhibitors. Bioorg. Med. Chem. 2018; 26(12): 3696-3706. DOI: 10.1016/j.bmc.2018.05.050